

Petrus JÄärvinen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4192025/publications.pdf>

Version: 2024-02-01

31
papers

451
citations

759233

12
h-index

752698

20
g-index

33
all docs

33
docs citations

33
times ranked

877
citing authors

#	ARTICLE	IF	CITATIONS
1	T and NK cell abundance defines two distinct subgroups of renal cell carcinoma. <i>Oncolmmunology</i> , 2022, 11, 1993042.	4.6	16
2	Active surveillance versus initial surgery in the long-term management of Bosniak IIFâ€“IV cystic renal masses. <i>Scientific Reports</i> , 2022, 12, .	3.3	5
3	The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgeryâ€”Results from RECUR Consortium. <i>European Urology Oncology</i> , 2021, 4, 473-482.	5.4	33
4	Should patients with lowâ€“risk renal cell carcinoma be followed differently after nephronâ€“sparing surgery vs radical nephrectomy?. <i>BJU International</i> , 2021, 128, 386-394.	2.5	5
5	Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients. <i>Modern Pathology</i> , 2021, 34, 2229-2241.	5.5	25
6	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
7	Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 413-419.	1.0	3
8	Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition. <i>Oncolmmunology</i> , 2020, 9, 1761229.	4.6	22
9	Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy. <i>PLoS ONE</i> , 2020, 15, e0235779.	2.5	8
10	Associations of PTEN and ERG with Magnetic Resonance Imaging Visibility and Assessment of Nonâ€“organ-confined Pathology and Biochemical Recurrence After Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 7, 1316-1323.	3.1	4
11	Title is missing!. , 2020, 15, e0235779.		0
12	Title is missing!. , 2020, 15, e0235779.		0
13	Title is missing!. , 2020, 15, e0235779.		0
14	Title is missing!. , 2020, 15, e0235779.		0
15	Clonal heterogeneity influences drug responsiveness in renal cancer assessed by <i>ex vivo</i> drug testing of multiple patientâ€“derived cancer cells. <i>International Journal of Cancer</i> , 2019, 144, 1356-1366.	5.1	29
16	Evolving Clinical Picture of Renal Cell Carcinoma: A Population-Based Study from Helsinki. <i>Urologia Internationalis</i> , 2019, 102, 390-398.	1.3	1
17	Decision Aids for Prostate Cancer Screening Choice. <i>JAMA Internal Medicine</i> , 2019, 179, 1072.	5.1	40
18	Randomized Trials Show a Consistent Benefit of Radical Prostatectomy on Mortality Outcomes. <i>Journal of Urology</i> , 2019, 202, 1106-1108.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. <i>Scandinavian Journal of Urology</i> , 2018, 52, 419-426.	1.0	16
20	Use of venous-thrombotic-embolic prophylaxis in patients undergoing surgery for renal tumors: a questionnaire survey in the Nordic countries (The NORENCA -2 study). <i>Research and Reports in Urology</i> , 2018, Volume 10, 181-187.	1.0	2
21	Patient Experience of Systematic Versus Fusion Prostate Biopsies. <i>European Urology Oncology</i> , 2018, 1, 202-207.	5.4	20
22	Carbonic anhydrase <sc>II</sc>: a novel biomarker for pseudomyxoma peritonei. <i>Apmis</i> , 2017, 125, 207-212.	2.0	11
23	Contemporary treatment of renal tumors: a questionnaire survey in the Nordic countries (the Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.0	9
24	Multiple components of PKA and TGF- β pathways are mutated in pseudomyxoma peritonei. <i>PLoS ONE</i> , 2017, 12, e0174898.	2.5	15
25	Repeat multiparametric MRI in prostate cancer patients on active surveillance. <i>PLoS ONE</i> , 2017, 12, e0189272.	2.5	23
26	Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. <i>Human Pathology</i> , 2016, 54, 47-54.	2.0	23
27	Outcome of surgery for patients with renal cell carcinoma and tumour thrombus in the era of modern targeted therapy. <i>Scandinavian Journal of Urology</i> , 2016, 50, 380-386.	1.0	12
28	Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry. <i>International Journal of Cancer</i> , 2015, 136, E282-9.	5.1	66
29	Hand-assisted laparoscopic versus open partial nephrectomy in patients with T1 renal tumor: Comparative perioperative, functional and oncological outcome. <i>Scandinavian Journal of Urology</i> , 2015, 49, 446-452.	1.0	1
30	Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin. <i>International Journal of Colorectal Disease</i> , 2014, 29, 999-1007.	2.2	23
31	Cardiac Stress Reactivity and Recovery of Novelty Seekers. <i>International Journal of Behavioral Medicine</i> , 2009, 16, 236-240.	1.7	6